Total returns

At 31 January 2017	1 mth %	3 mths %	6 mths %	1 yr %	3 yrs % p.a.	5 yrs % p.a.	7 yrs % p.a.	Inception % p.a. (Feb 2008)
Ralton Australian Shares	-0.55	7.42	5.75	18.76	11.64	14.05	10.16	7.44
Income return	*0.00*	*0.51*	*1.67*	*4.38*	*4.06*	*4.15*	*4.28*	*4.33*
Growth return	*-0.55*	*6.91*	*4.09*	*14.37*	*7.58*	*9.90*	*5.88*	*3.11*
S&P/ASX 300 Accum. Index	-0.77	6.44	3.03	17.32	7.37	10.36	7.54	4.40
Difference	**0.23**	**0.98**	**2.73**	**1.44**	**4.27**	**3.69**	**2.61**	**3.04**

Performance review

- The S&P/ASX 300 Accumulation Index recorded a modest fall in January, -0.77%. Materials and Healthcare were both up solidly, Real Estate and Industrials were both down for the month.
- For the month, the Ralton Australian Shares portfolio returned -0.55%, outperforming the benchmark by 0.22%.
- For January, our overweight position in Energy was a key contributor to investor returns, whereas being underweight Materials detracted from relative returns

Performance attribution

Key contributors

Key contributors	Positioning
Origin Energy Ltd	Overweight
Boral Limited	Overweight
CSL Limited	Overweight

Origin Energy (ORG, +7.6%) – added value in January and the stock is now up 73% from its level a year ago. We see several drivers for the recent outperformance: a) delivery of two LNG trains at the APLNG plant in Gladstone, b) an overall simplification of the business with material cost savings from a reduction in headcount as APLNG construction winds down and productivity improves across the Energy Markets (utility) division, c) debt reduction from asset sales and improving operational cash flow, and d) the recovery in the oil price (which benefits its LNG production) following initiatives by OPEC to manage supply down to lift prices.

The new CEO, Frank Calabria, has signaled his intention to reduce debt further and simplify the business via the proposed IPO of various assets. We support the concept of the IPO, assuming ORG does not damage its long-term value by limiting its access to the gas assets to be housed in the new vehicle. ORG's access to both equity and contracted gas supply in a tightening East Coast market was central to our ORG investment thesis. No doubt Calabria understands the critical nature of these arrangements and the need to preserve and generate value for both parties.

Boral Limited (BLD, +7.6%) – shares rebounded in January as investors began to focus on the fundamentals of the Headwaters acquisition. As we highlighted last month, the acquisition is consistent with CEO Mike Kane's long-flagged strategy of expanding BLD's presence in the US to gain more exposure to the US housing cycle. Assuming the transaction passes all regulatory hurdles, Headwaters' and BLD's existing US operations will then account for nearly 45% of BLD's profits.

The key deliverables from the Headwaters acquisition for shareholders will be BLD's delivery of the synergy target, otherwise the acquisition will look very expensive. Further, we expect the US housing cycle has a few more years before it peaks, with volumes currently running well below a typical mid-cycle run-rate for US housing starts. Finally, what appears to have been overlooked at present are the tax losses BLD holds in the US and the tax shelter that will be created from the amortisation of acquired goodwill in the US. Both of these items will provide a substantial benefit to BLD from a cash-flow perspective and will facilitate a material reduction in BLD's debt levels post transaction.

CSL Limited (CSL, +11.8%) – blood plasma producer, CSL, upgraded its profit forecasts in January and it is now targeting 18-20% profit growth in constant currency for FY17. CSL attributed the profit uplift to several factors, including market share gains for its core blood plasma products in the US, a factor which we principally attribute to CSL's investment foresight. Investors often comment on CSL's heavy investment in R&D for new products, however we would also highlight CSL's ongoing investment in both its 'fleet' of US blood collection sites and manufacturing capability globally. In terms of new blood collection sites, our sense is that CSL has capitalised on industry conditions, noting that its peers are either capital constrained or distracted by recent acquisitions. As a result, CSL's recent expansion looks set to cement a material competitive advantage in plasma supply given the lag time between opening new sites, drawing blood (so to speak) and producing finished goods (or plasma inventories). In practical terms, the need for blood samples to be stored during production while samples are tested sequentially for contamination, means blood product spends upwards of a year in inventory, reinforcing CSL's current supply advantage.

Key detractors

Key detractors	Positioning
Brambles Limited	Overweight
Ainsworth Gaming Technology Limited	Overweight
Star Entertainment Group Ltd	Overweight

Brambles (BXB, -16.1%) – global pallet company, Brambles, shocked investors with a profit downgrade, reducing first-half profit expectations to 3% growth for the period from an expected double-digit level. Our thesis around BXB has focused on strong growth opportunities across its pallet operations, as supply chains become ever more sophisticated and customers seek efficiencies – savings and scale benefits via access to BXB's pallet pool. Recent results, both revenue and profit growth, together with BXB's ability to deploy growth capital expenditure, have supported this view. In this context, a profit downgrade certainly highlighted an unexpected change in momentum for the business. Outgoing CEO, Tom Gorman, cited a destocking of inventory across its customers, together with customers deferring on new business commitments as the principal reasons behind the BXB revenue shortfall. All the issues were focused on the US pallet business, with the balance of BXB's global operations performing in line with company and market expectations. Consistent with a tight election race, where US businesses were likely a winner or loser under a Trump or Clinton presidency and their respective policies, the pause in business decision-making makes some sense. To summarise, our current sense is that BXB's customer proposition and the strength of the investment thesis is undiminished. We are however, keen to hear the company's update during the February reporting season as we will gauge the comments from incoming CEO, Graham Chipchase, for any change in direction.

Ainsworth Game Technology (AGI, -14.2%) – shares detracted from portfolio returns. The share price has been under pressure from its falling market share in Australian gaming markets, culminating in a recent profit downgrade late last year. We believe AGI's market share has reached or is very close to bottoming in Australia. Also, its US market share continues to move higher, which is reinforced by AGI's increased spend in R&D and corporate costs. In the short term, these are a headwind to profits, but as we have seen with Aristocrat, they will drive innovation and future product development, which ultimately drives revenue growth. Secondly, the technology (games library) support from new shareholder, Novomatics, together with European sales opportunity and the presence Novomatics has committed to as part of the Ainsworth transaction, is expected to be a benefit to AGI's unit volumes and profits.

The Star Entertainment Group (SGR, -7.7%) – was under pressure in the final quarter of 2016 and this selling pressure appears to have filtered through into January. Specifically, sentiment around VIP gamblers in the wake of the arrest of Crown's Asian-based sales team, together with a mixed trading update at the AGM in October highlighting a slowdown in growth at key Australian venues, has weighed on SGR shares. The weaker performance from the Sydney and Gold Coast casinos was due to the significant capital works being undertaken at the sites. As this work is completed, we would expect to see the second-half performance improve. In relation to VIP gaming, it accounts for less than 15% of group profit, so weakness is unhelpful at the margin, that is, it is not the main game. We continue to focus on the medium term and believe our thesis for SGR remains intact.

Portfolio changes

Key additions and material adjustments

We did not purchase any stocks during the month.

Key disposals and material adjustments

Sold
Incitec Pivot (IPL)

We sold our long-held position in **Incitec Pivot (IPL)** in January. With the long-awaited US ammonia plant, 'Waggaman', having recently commenced operations and the price for ammonia, urea and DAP all bouncing off recent lows, we took the opportunity to exit the position, capturing the solid move in the share price in recent months. Our pragmatic view, taking into account several of the volatile inputs and moving parts that typically influence IPL's customers, end markets and share price, is that the risk/reward was now less favourable.

Sector allocation

GICS sector	Ralton	Index	+/-
Consumer Discretionary	10.0%	6.1%	3.9%
Energy	7.3%	4.5%	2.8%
Information Technology	3.8%	1.5%	2.3%
Consumer Staples	7.9%	6.6%	1.3%
Telecommunication Services	5.6%	4.6%	0.9%
Financials	34.8%	34.5%	0.3%
Utilities	2.8%	2.6%	0.3%
Health Care	6.1%	7.1%	-0.9%
Materials	16.1%	17.2%	-1.1%
Industrials	5.6%	7.1%	-1.5%
Real Estate	0.0%	8.3%	-8.3%
Total	**100.0%**	**100.0%**	**0.0%**

Top 10 holdings#

Company name	ASX code
BHP Billiton Limited	BHP
Commonwealth Bank.	CBA
Westpac Banking Corp	WBC
National Aust. Bank	NAB
Woolworths Limited	WOW
Aristocrat Leisure	ALL
QBE Insurance Group	QBE
CSL Limited	CSL
ANZ Banking Grp Ltd	ANZ
Telstra Corporation.	TLS

Performance comparison of $20,000*



CONTACT COPIA

1800 442 129 | clientservices@copiapartners.com.au | copiapartners.com.au

John Clothier	General Manager, Distribution	0408 488 549 | jclothier@copiapartners.com.au
Adam Tweedale	State Manager, Southern Region	0425 804 727 | atweedale@copiapartners.com.au
Angela Vincent	State Manager, Northern Region	0477 347 260 | avincent@copiapartners.com.au
Sean Paul McGoldrick	Account Manager, Northern Region	0421 050 370 | spmcgoldrick@copiapartners.com.au
Iain Mason	Director, Institutional Business	0412 137 424 | imason@copiapartners.com.au

Performance of the Ralton Wholesale Australian Shares Model Portfolio is based on a model portfolio and is gross of investment management and administration fees, but net of transaction costs. The total return performance figures quoted are historical and do not allow the effects of income tax or inflation. Total returns assume the reinvestment of all portfolio income. Past performance is not a reliable indicator of future performance.

*The performance comparison of $20,000 over 5 years is for illustrative purposes only. Performance is calculated on a gross basis. Actual performance will vary depending on the amount of fees charged by the relevant platform that a client uses to implement the portfolio. The comparison with the S&P/ASX 300 Accumulation Index is for comparative purposes only. Index returns do not allow for transaction, management, operational or tax costs. An index is not managed and investors cannot invest directly an in index. There is no guarantee these objectives will be met.

#Portfolio holdings may not be representative of current or future recommendations for the portfolio. The securities listed may not represent all of the recommended portfolio's holdings. Future recommended portfolio holdings may not be profitable.

This document is for general information only and does not take into account the specific investment objectives, financial situation or particular needs of any specific reader. As such, before acting on any information contained in this document, readers should consider whether the information is suitable for their needs. This may involve seeking advice from a qualified financial adviser. Ralton Asset Management (AFSL 298210, ABN 45 114 924 382) (Ralton) is the provider of the Ralton Wholesale Australian Shares Model Portfolio. To subscribe, contact Copia Investment Partners Ltd (AFSL 229316, ABN 22 092 872 056) (Copia) by calling 1800 442 129 or email clientservices@copiapartners.com.au. Any opinions or recommendations contained in this document are subject to change without notice. Ralton and Copia are under no obligation to update or keep information contained in this document current.